REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new chemotherapy combination called CPX-351 in adults with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and under…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New drug combo aims to control aggressive blood disorder
Disease control Recruiting nowThis study is testing a targeted drug called enasidenib, sometimes combined with another drug (azacitidine), for people with a high-risk type of blood and bone marrow disorder called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for tough blood cancers: Four-Drug attack trial opens
Disease control Recruiting nowThis trial is testing whether adding a newer targeted drug (quizartinib) to a standard three-drug chemotherapy cocktail works better for controlling aggressive blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It is for adults (18-65 fo…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC